Gene set shows which patients benefit from chemo after surgery
September 8th, 2010 - 4:40 pm ICT by ANIWashington, Sep 08 (ANI): Scientists have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery.
The study, advances the 2005 findings of the NCIC Clinical Trials Group study JBR.10, conducted in collaboration with the U.S. National Cancer Institute.
The JBR.10 findings showed significant survival benefit from the anti-cancer drugs vinorelbine and cisplatin in patients with early-stage (stage I and II) non-small cell lung cancer whose tumors had been surgically removed.
Principal investigator Dr. Ming Tsao, pathologist at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN), and Professor of Laboratory Medicine and Pathobiology at the University of Toronto research team and collaborators at NCIC Clinical Trials Group at Queen’s University performed a genetic analysis of tumor tissue from 133 of the 482 patients from the JBR.10 study who had banked frozen tumor samples.
The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).
They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease experienced the greatest benefit from chemotherapy - with a 67 percent reduction in the risk of death - while chemotherapy did not reduce the risk of death in patients designated as low risk.
While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao’s study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post-operative chemotherapy.
The study has been published online in the Journal of Clinical Oncology (JCO 64325). (ANI)
- Gene signature may help spot patients at colon cancer recurrence risk - Feb 27, 2010
- Radiation ineffective after mastectomy, says study - Mar 07, 2010
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- Frequent CT scanning for testicular cancer linked to secondary cancers - Mar 31, 2011
- Lymph node removal 'not always needed in early-stage breast cancer' - Feb 09, 2011
- Circulating tumour cells in blood up death risk in early-stage breast cancer patients - Dec 11, 2010
- New tool for early detection of ovarian cancer - May 21, 2010
- Biomarker-based blood test can predict metastasis risk in melanoma - Apr 16, 2011
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- Alcohol intake after breast cancer diagnosis may increase recurrence risk - Sep 16, 2010
- Bone drug may help fight breast cancer - Jun 03, 2010
- Shark cartilage does not improve lung cancer survival - May 27, 2010
- Don't count on selenium to prevent lung cancer, suggests study - Jun 06, 2010
- Chemo-radiotherapy prevents bladder cancer recurrences - Oct 26, 2010
- Tumour-free Michael Douglas 'at risk for recurrence' - Jan 12, 2011
Tags: aggressive disease, cancer drugs, cancer program, cell lung cancer, clinical trials group, disease recurrence, genetic signature, national cancer institute, ncic clinical trials group, non small cell lung cancer, pathobiology, princess margaret hospital, small cell lung cancer, survival benefit, tsao, tumor samples, tumor tissue, university health network, university of toronto, vinorelbine